4 Analysts Assess Denali Therapeutics: What You Need To Know
Portfolio Pulse from Benzinga Insights
Four analysts have recently updated their ratings on Denali Therapeutics (NASDAQ:DNLI), showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $65.75, a significant decrease from the previous $105.00. Analyst actions include lowering and maintaining ratings, with price targets ranging from $31.00 to $95.00. Denali Therapeutics, a biotech company focused on neurodegeneration diseases, has seen a -64.4% decline in revenue growth and faces financial health challenges, including a net margin of -7841.59% and an ROE of -8.62%.
February 28, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Denali Therapeutics has received mixed analyst ratings, with a new average price target of $65.75, reflecting a decrease from $105. The company's financial health is under scrutiny due to a significant revenue decline and poor profitability indicators.
The significant decrease in the average price target, combined with the company's reported financial challenges, such as a drastic revenue decline and poor profitability metrics, suggest a negative short-term impact on DNLI's stock price. Analysts' mixed ratings and adjustments in price targets reflect concerns over the company's current financial health and market position, likely influencing investor sentiment negatively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100